Expert Interview
Discussing BeiGene's anti–PD-1 antibody, tislelizumab in gastric adenocarcinoma and the results of the RATIONALE-305 study presented at ESMO 2023
Ticker(s): BGNEInstitution: Boston University School of Medicine
- Assistant Professor of Medicine and Medical Oncologist in the section of Hematology/Oncology at Boston Medical Center.
- Manages 75 patients with cholangiocarcinoma and 75-100 patients with either gastric or GE junction adenocarcinoma
- Research focuses on studying prognostic biomarkers in pancreatic NETs, being PI on several trials; Clinical focus on gastrointestinal malignancies.
Please describe your practice as a clinician,how many patients with gastric or GE junction adenocarcinoma do you treat on a yearly basis? Could you walk us through the standard of care, and tell us a bit about the most promising upcoming treatments, or interesting clinical trials in this space.
Are the results from the final analysis presented at ESMO from the Phase 3 RATIONALE-305 shocking or expected?
What would you rate your level of excitement for Tislelizumab in the gastric cancer space? (Scale; 1- least to 10- most)
Added By: sara_admin- Are there any emerging therapies in this indication that might compete or eventually compete in the space and anything you're excited about?
- Is the Ventana SP263 assay analogous to the 5% that you're seeing in practice?
- What's your high-level view on the results of the RATIONALE-305 trial with tislelizumab?
- Is the control arm of the trial equivalent to the FOLFOX regimen?
- Is there any differentiating factor or anything that would cause tislelizumab to stand out or make it appealing to use as opposed to the two that you're already using in this setting?
- Did the placebo group perform differently as well in this trial or the same as in those trials?
- Does this data appear to be approvable by the FDA?
- Was there anything surprising about the forest plot for overall survival?
- Are you looking to try out tislelizumab, or is there no reason to really even mess with that?
Added By: slingshot_insights
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
